
Guthrie's fundraising profile is heavily weighted toward institutional money, with PACs and committees accounting for 71 percent of his $10.7 million raised. His industry-tied contributions show concentration in health services and pharmaceuticals, along with notable support from lawyers, lobbyists, and telecommunications firms, patterns visible both in his overall donor base and among individual donors specifically. His voting record includes 336 recorded votes with no stock trade disclosures on file.
FOLLOW THE MONEY
Left: who funds Guthrie (ribbon width = dollars) · right: their votes on bills classified as favoring vs limiting those sectors
“Favors / limits” is an AI classification of each bill's likely effect on the sector — a factual reading of the bill, not a claim about motive. Correlation, not causation. The named bills are in DOES THE MONEY MATCH THE VOTES? below.
DOES THE MONEY MATCH THE VOTES?
How Guthrie voted on bills touching their biggest donor sectors · 6 of 20 shown, ranked by sector money
Each dollar figure is Guthrie's total from that donor sector — shown on each related vote, not a per-vote amount. Correlation between funding and votes, not causation; many factors shape any single vote.
TOP SOURCES
ATT
employees
employees
MEHLMAN CONSULTING
employees
COMCAST
employees
BGR GROUP
employees
ALIGNMENT SIGNALS
Brett Guthrie (R) chairs the Energy and Commerce committee overseeing Health Services — their largest tracked donor sector (23%)
Rep. Brett Guthrie (R-KY) chairs the House Committee on Energy and Commerce, which has jurisdiction over the Health Services sector. Health Services comprises 22.7% of his identifiable donor base ($2.43M), ranking 8th among House Republicans in donor concentration from this sector.
Brett Guthrie (R) voted YEA on 11 of 11 bills classified as favoring their donor sectors — #3 rate in the House
Brett Guthrie voted yes on 100% of tracked bills classified as favoring Pharmaceuticals & Biotech and Telecommunications—the third-highest rate among House members with sufficient votes on such legislation. He voted yes on HR3537-117, which sought to accelerate access to therapies for ALS patients, a bill classified as favoring the pharmaceutical sector, though he voted yes on 4 of 5 bills classified as limiting those same industries.
LEGISLATION
2 sponsored
COMMITTEES
SIMILAR DONOR NETWORKS
Members funded by the same industries — overlapping donor networks may reflect shared policy interests.

H. Morgan Griffith
R-VA · House

Diana DeGette
D-CO · House

Neal P. Dunn
R-FL · House

John Joyce
R-PA · House

Gus M. Bilirakis
R-FL · House

Frank Pallone, Jr.
D-NJ · House